AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $213.72M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.08M
Average 0.32M
ACIU Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
AC Immune S.A.NASDAQ: ACIU
Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025
Capital expenditures grows, but more slowly than its trailing trend
Q4 FY2025 capital expenditures of CHF 107.16K (cash outflow) rose 19.1% year over year, behind the +56.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 84.8% from the prior quarter. Over 3 fiscal years it compounded at -11.5% a year.
Context
- Capital expenditures amounted to 24.1% of revenue in FY2025, up 21.9 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +19.1% toward the trailing-twelve-month pace of +56.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
CHF · from the cash flow
- Latest · FY2025
- (859.54K) CHF
- Year-over-year change
- -49.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (859.54K) | -49.2% |
| FY2024 | 2024-12-31 | (576K) | +28.1% |
| FY2023 | 2023-12-31 | (801K) | +35.4% |
| FY2022 | 2022-12-31 | (1.24M) | +53.0% |
| FY2021 | 2021-12-31 | (2.64M) | — |
Capital Expenditures vs competitors
How ACIU compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +56.3% is the 2nd highest of 8, against a peer median of -29.2%.
- Capital expenditures amounts to 25.2% of revenue for ACIU, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.69M USD | +140168207.3% | — | 7.8% | |
| LTM Dec 2025 | $6.08M USD | — | +88.7% | — | |
| LTM Mar 2026 | $2.23M USD | -44.0% | -1.0% | 3.3% | |
| LTM Dec 2025 | CHF 900.16K CHF | +56.3% | -11.5% | 25.2% | |
| LTM Mar 2026 | $623K USD | -8.4% | -68.2% | 2009.7% | |
| LTM Mar 2026 | $556K USD | -70.3% | -68.0% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $496K USD | +19.8% | +25.1% | — |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| LTM Mar 2026 | $63K USD | -29.2% | -72.4% | — | |
| LTM Mar 2026 | $1.52K USD | -99.5% | +15.4% | 0.3% | |
| LTM Mar 2026 | $4 USD | — | — | — | |
| Peer median (excluding ACIU) | — | -29.2% | -27.2% | 7.8% | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (67.28M) |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.39M |
| Deferred Income Tax | 130K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.13M | 3.33M | 4.37M | 5.47M | 0 |
| Change in Working Capital | 6.84M | (8.43M) | (15.16M) | 107.51M | (6.47M) |
| Accounts Receivables | (99K) | 603K | (14.8M) | 13.55M | 877.68K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | (565.39K) |
| Other Working Capital | 6.94M | (9.04M) | (360K) | 93.96M | (6.78M) |
| Other Non-Cash Items | (6.2M) | (72K) | 2.41M | 1.61M | 5.21M |
| Operating Cash Flow | (65.69M) | (73.57M) | (60.41M) | 65.84M | (66.15M) |
| Capital Expenditures | (2.64M) | (1.24M) | (801K) | (576K) | (859.54K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 14.33K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 61.69M |
| Other Investing Activities | (51.03M) | 25M | 66.45M | (104.71M) | (162.36K) |
| Investing Cash Flow | (53.66M) | 23.76M | 65.65M | (105.29M) | 60.69M |
| Debt Repayment | 22.95M | (569K) | (548K) | (683K) | (1.03M) |
| Common Stock Issued | 17.8M | 7K | 43.8M | 111K | 5.73K |
| Common Stock Repurchased | 0 | (8K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6K) | (776K) | 0 | (548K) | 46.13K |
| Financing Cash Flow | 40.75M | (1.35M) | 43.25M | (1.12M) | (974.14K) |
| Effect of Forex Changes | (70K) | 521K | (1.58M) | (1.65M) | 1.51M |
| Net Change in Cash | (78.68M) | (50.63M) | 46.91M | (42.22M) | (4.92M) |
| Free Cash Flow | (68.32M) | (74.81M) | (61.21M) | 65.27M | (67.01M) |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.